Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease

Raja Affendi Raja Ali, Cara Dooley, Harry Comber, John Newell, Laurence John Egan

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background & Aims: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC), indicating that inflammation might alter tumor characteristics and potentially affect treatment and survival. Published data on this topic are inconclusive, so we conducted a population-based study in Ireland to address it. Methods: We used the National Cancer Registry to collect data on all patients diagnosed with CRC in Ireland from 1994 to 2005 (n = 22,335) and identified those who also had IBD (n = 170). The clinical characteristics, treatment, and survival of patients with IBD and CRC were compared with those of patients with CRC without IBD. Results: Patients with CRC and IBD were, on average, 7.7 years younger than those without IBD at diagnosis of CRC (P = .001), and were less likely to smoke (P = .002). Fewer CRCs in patients with IBD were stage 4 at diagnosis (12% vs 22% in non-IBD patients; P < .001). There was no significant difference in CRC treatment modalities between patients with or without IBD (P = .57). The median survival time of CRC patients with IBD was about 3 years longer than that of patients without IBD (P < .001). However, Cox proportional hazards analysis revealed that IBD was not a significant prognostic factor for CRC (P = .97). However, older age, male sex, smoking, and advanced grade and stage all were associated independently with shorter survival time. When propensity score matching was used to analyze outcomes, the survival times of CRC patients with and without IBD did not differ significantly. Conclusions: The features of patients with CRC and IBD differ significantly from those of CRC patients without IBD, but each group of patients receive similar treatment and have similar patterns of disease progression after diagnosis.

Original languageEnglish
Pages (from-to)584-589
Number of pages6
JournalClinical Gastroenterology and Hepatology
Volume9
Issue number7
DOIs
Publication statusPublished - Jul 2011
Externally publishedYes

Fingerprint

Inflammatory Bowel Diseases
Colorectal Neoplasms
Survival
Therapeutics
Ireland
Propensity Score
Survival Analysis
Smoke
Registries
Disease Progression
Neoplasms
Smoking

Keywords

  • Colon Cancer
  • Inflammation
  • Prognosis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease. / Raja Ali, Raja Affendi; Dooley, Cara; Comber, Harry; Newell, John; Egan, Laurence John.

In: Clinical Gastroenterology and Hepatology, Vol. 9, No. 7, 07.2011, p. 584-589.

Research output: Contribution to journalArticle

@article{4aafc8217bb947ed9926b576e768b1b8,
title = "Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease",
abstract = "Background & Aims: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC), indicating that inflammation might alter tumor characteristics and potentially affect treatment and survival. Published data on this topic are inconclusive, so we conducted a population-based study in Ireland to address it. Methods: We used the National Cancer Registry to collect data on all patients diagnosed with CRC in Ireland from 1994 to 2005 (n = 22,335) and identified those who also had IBD (n = 170). The clinical characteristics, treatment, and survival of patients with IBD and CRC were compared with those of patients with CRC without IBD. Results: Patients with CRC and IBD were, on average, 7.7 years younger than those without IBD at diagnosis of CRC (P = .001), and were less likely to smoke (P = .002). Fewer CRCs in patients with IBD were stage 4 at diagnosis (12{\%} vs 22{\%} in non-IBD patients; P < .001). There was no significant difference in CRC treatment modalities between patients with or without IBD (P = .57). The median survival time of CRC patients with IBD was about 3 years longer than that of patients without IBD (P < .001). However, Cox proportional hazards analysis revealed that IBD was not a significant prognostic factor for CRC (P = .97). However, older age, male sex, smoking, and advanced grade and stage all were associated independently with shorter survival time. When propensity score matching was used to analyze outcomes, the survival times of CRC patients with and without IBD did not differ significantly. Conclusions: The features of patients with CRC and IBD differ significantly from those of CRC patients without IBD, but each group of patients receive similar treatment and have similar patterns of disease progression after diagnosis.",
keywords = "Colon Cancer, Inflammation, Prognosis",
author = "{Raja Ali}, {Raja Affendi} and Cara Dooley and Harry Comber and John Newell and Egan, {Laurence John}",
year = "2011",
month = "7",
doi = "10.1016/j.cgh.2011.04.016",
language = "English",
volume = "9",
pages = "584--589",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease

AU - Raja Ali, Raja Affendi

AU - Dooley, Cara

AU - Comber, Harry

AU - Newell, John

AU - Egan, Laurence John

PY - 2011/7

Y1 - 2011/7

N2 - Background & Aims: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC), indicating that inflammation might alter tumor characteristics and potentially affect treatment and survival. Published data on this topic are inconclusive, so we conducted a population-based study in Ireland to address it. Methods: We used the National Cancer Registry to collect data on all patients diagnosed with CRC in Ireland from 1994 to 2005 (n = 22,335) and identified those who also had IBD (n = 170). The clinical characteristics, treatment, and survival of patients with IBD and CRC were compared with those of patients with CRC without IBD. Results: Patients with CRC and IBD were, on average, 7.7 years younger than those without IBD at diagnosis of CRC (P = .001), and were less likely to smoke (P = .002). Fewer CRCs in patients with IBD were stage 4 at diagnosis (12% vs 22% in non-IBD patients; P < .001). There was no significant difference in CRC treatment modalities between patients with or without IBD (P = .57). The median survival time of CRC patients with IBD was about 3 years longer than that of patients without IBD (P < .001). However, Cox proportional hazards analysis revealed that IBD was not a significant prognostic factor for CRC (P = .97). However, older age, male sex, smoking, and advanced grade and stage all were associated independently with shorter survival time. When propensity score matching was used to analyze outcomes, the survival times of CRC patients with and without IBD did not differ significantly. Conclusions: The features of patients with CRC and IBD differ significantly from those of CRC patients without IBD, but each group of patients receive similar treatment and have similar patterns of disease progression after diagnosis.

AB - Background & Aims: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC), indicating that inflammation might alter tumor characteristics and potentially affect treatment and survival. Published data on this topic are inconclusive, so we conducted a population-based study in Ireland to address it. Methods: We used the National Cancer Registry to collect data on all patients diagnosed with CRC in Ireland from 1994 to 2005 (n = 22,335) and identified those who also had IBD (n = 170). The clinical characteristics, treatment, and survival of patients with IBD and CRC were compared with those of patients with CRC without IBD. Results: Patients with CRC and IBD were, on average, 7.7 years younger than those without IBD at diagnosis of CRC (P = .001), and were less likely to smoke (P = .002). Fewer CRCs in patients with IBD were stage 4 at diagnosis (12% vs 22% in non-IBD patients; P < .001). There was no significant difference in CRC treatment modalities between patients with or without IBD (P = .57). The median survival time of CRC patients with IBD was about 3 years longer than that of patients without IBD (P < .001). However, Cox proportional hazards analysis revealed that IBD was not a significant prognostic factor for CRC (P = .97). However, older age, male sex, smoking, and advanced grade and stage all were associated independently with shorter survival time. When propensity score matching was used to analyze outcomes, the survival times of CRC patients with and without IBD did not differ significantly. Conclusions: The features of patients with CRC and IBD differ significantly from those of CRC patients without IBD, but each group of patients receive similar treatment and have similar patterns of disease progression after diagnosis.

KW - Colon Cancer

KW - Inflammation

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=79959335314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959335314&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2011.04.016

DO - 10.1016/j.cgh.2011.04.016

M3 - Article

VL - 9

SP - 584

EP - 589

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 7

ER -